{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:11:13Z","timestamp":1715940673589},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s11886-016-0706-0","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T09:22:59Z","timestamp":1454491379000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antithrombotic Therapy After Peripheral Vascular Intervention"],"prefix":"10.1007","volume":"18","author":[{"given":"Peter","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schuyler","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"706_CR1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jacc.2011.10.860","volume":"59","author":"MA Creager","year":"2012","unstructured":"Creager MA, Belkin M, Bluth EI, et al. 2012 ACCF\/AHA\/ACR\/SCAI\/SIR\/STS\/SVM\/SVN\/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol [Internet]. 2012;59:294\u2013357.","journal-title":"J Am Coll Cardiol [Internet]"},{"key":"706_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/CIRCULATIONAHA.111.033886","volume":"126","author":"JS Berger","year":"2012","unstructured":"Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 2012;126:491\u2013500.","journal-title":"Circulation."},{"key":"706_CR3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/1358863X11424312","volume":"16","author":"TW Rooke","year":"2011","unstructured":"Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF\/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Vasc Med. 2011;16:452\u201376.","journal-title":"Vasc Med"},{"key":"706_CR4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCRESAHA.114.303517","volume":"116","author":"MM McDermott","year":"2015","unstructured":"McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. Circ Res [Internet]. 2015;116:1540\u201350.","journal-title":"Circ Res [Internet]"},{"key":"706_CR5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","volume":"124","author":"RL Pande","year":"2011","unstructured":"Pande RL, Perlstein TS, Beckman JA, et al. Secondary prevention and mortality in peripheral artery disease: national health and nutrition examination study, 1999 to 2004. Circulation. 2011;124:17\u201323.","journal-title":"Circulation."},{"key":"706_CR6","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","volume":"120","author":"C Diehm","year":"2009","unstructured":"Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053\u201361.","journal-title":"Circulation."},{"key":"706_CR7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2005.09.074","volume":"47","author":"HHH Feringa","year":"2006","unstructured":"Feringa HHH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47:1182\u20137.","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"706_CR8","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","volume":"32","author":"M Tendera","year":"2011","unstructured":"Tendera M, Aboyans V, Bartelink M-L, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatm. Eur Heart J. 2011;32(22):2851\u2013906.","journal-title":"Eur Heart J"},{"key":"706_CR9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/CIRCULATIONAHA.111.059048","volume":"126","author":"DP Slovut","year":"2012","unstructured":"Slovut DP, Lipsitz EC. Surgical technique and peripheral artery disease. Circulation. 2012;126:1127\u201338.","journal-title":"Circulation."},{"key":"706_CR10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jvs.2009.01.035","volume":"50","author":"PP Goodney","year":"2009","unstructured":"Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg [Internet]. 2009;50:54\u201360.","journal-title":"J Vasc Surg [Internet]"},{"key":"706_CR11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacc.2014.12.048","volume":"65","author":"WS Jones","year":"2015","unstructured":"Jones WS, Mi X, Qualls LG, Vemulapalli S, Peterson ED, Patel MR, et al. Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. J Am Coll Cardiol. 2015;65:920\u20137. This study showed the shift in PVI location from an inpatient setting to outpatient\/office-based clinic setting.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"706_CR12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","volume":"301","author":"JS Berger","year":"2009","unstructured":"Berger JS, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909\u201319.","journal-title":"JAMA"},{"key":"706_CR13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCRESAHA.114.303505","volume":"116","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Creager MA. Pharmacological treatment and current management of peripheral artery disease. Circ Res. 2015;116:1579\u201398.","journal-title":"Circ Res"},{"key":"706_CR14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","journal-title":"BMJ"},{"key":"706_CR15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","volume":"52","author":"JJ Belch","year":"2010","unstructured":"Belch JJ, Dormandy J, Committee CW, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg [Internet]. 2010;52:825\u201333. 833 e1\u20132.","journal-title":"J Vasc Surg [Internet]"},{"key":"706_CR16","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.","journal-title":"BMJ."},{"key":"706_CR17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","volume":"301","author":"JS Berger","year":"2009","unstructured":"Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA [Internet]. 2009;301:1909\u201319.","journal-title":"JAMA [Internet]"},{"key":"706_CR18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","volume":"261","author":"M Catalano","year":"2007","unstructured":"Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276\u201384.","journal-title":"J Intern Med"},{"key":"706_CR19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FG Fowkes","year":"2010","unstructured":"Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841\u20138.","journal-title":"JAMA"},{"issue":"1","key":"706_CR20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1078-5884(05)80200-X","volume":"10","author":"D Bergqvist","year":"1995","unstructured":"Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg. 1995;10(1):69\u201376.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"5","key":"706_CR21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2796.1990.tb00164.x","volume":"227","author":"L Janzon","year":"1990","unstructured":"Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227(5):301\u20138.","journal-title":"J Intern Med"},{"key":"706_CR22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"M Gent","year":"1996","unstructured":"Gent M. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329\u201339.","journal-title":"Lancet."},{"key":"706_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","volume":"30","author":"PP Cacoub","year":"2009","unstructured":"Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Hear J. 2009;30:192\u2013201.","journal-title":"Eur Hear J"},{"key":"706_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ahj.2004.03.028","volume":"148","author":"DL Bhatt","year":"2004","unstructured":"Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Hear J. 2004;148:263\u20138.","journal-title":"Am Hear J"},{"key":"706_CR25","unstructured":"AstraZeneca. A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID). In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US). 2000- [cited 2015 Nov 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01732822 NLM Identifier: NCT01732822."},{"key":"706_CR26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","volume":"127","author":"MP Bonaca","year":"2013","unstructured":"Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation [Internet]. 2013;127:1522\u20139. 1529e1\u20136. This study was a subgroup analysis from a large randomized controlled study that has led to the US Food and Drug Administration approval of vorapaxar.","journal-title":"Circulation [Internet]"},{"key":"706_CR27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCRESAHA.116.303503","volume":"116","author":"AK Thukkani","year":"2015","unstructured":"Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res [Internet]. 2015;116:1599\u2013613.","journal-title":"Circ Res [Internet]"},{"key":"706_CR28","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.106.621391","volume":"116","author":"CJ White","year":"2007","unstructured":"White CJ, Gray WA. Endovascular therapies for peripheral arterial disease: an evidence-based review. Circulation. 2007;116:2203\u201315.","journal-title":"Circulation."},{"key":"706_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rvm.2013.11.001","volume":"2","author":"MB Forte","year":"2014","unstructured":"Forte MB, Becattini C, Agnelli G. Latest developments in antithrombotic therapy in patients with lower extremity arterial disease. Rev Vasc Med [Internet]. 2014;2:37\u201342.","journal-title":"Rev Vasc Med [Internet]"},{"key":"706_CR30","first-page":"369","volume":"27","author":"Z Krajcer","year":"2000","unstructured":"Krajcer Z, Howell MH. Update on endovascular treatment of peripheral vascular disease: new tools, techniques, and indications. Tex Heart Inst J [Internet]. 2000;27:369\u201385.","journal-title":"Tex Heart Inst J [Internet]"},{"key":"706_CR31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation [Internet]. 2015;131:495\u2013502.","journal-title":"Circulation [Internet]"},{"key":"706_CR32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2012.12.118","volume":"6","author":"T Zeller","year":"2013","unstructured":"Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv [Internet]. 2013;6:274\u201381.","journal-title":"JACC Cardiovasc Interv [Internet]"},{"key":"706_CR33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcin.2013.05.022","volume":"7","author":"D Scheinert","year":"2014","unstructured":"Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv [Internet]. 2014;7:10\u20139.","journal-title":"JACC Cardiovasc Interv [Internet]"},{"key":"706_CR34","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa051303","volume":"354","author":"M Schillinger","year":"2006","unstructured":"Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med [Internet]. 2006;354:1879\u201388.","journal-title":"N Engl J Med [Internet]"},{"key":"706_CR35","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","volume":"141","author":"P Alonso-Coello","year":"2012","unstructured":"Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest [Internet]. 2012;141:e669S\u201390S. This is the only published guideline that has recommendations for type of anti-thrombotic therapy after PVI.","journal-title":"Chest [Internet]"},{"key":"706_CR36","first-page":"18","volume":"7","author":"A Vison\u00e0","year":"2009","unstructured":"Vison\u00e0 A, Tonello D, Zalunardo B, et al. Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. Blood Transfus [Internet]. 2009;7:18\u201323.","journal-title":"Blood Transfus [Internet]"},{"key":"706_CR37","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","volume":"32","author":"M Tendera","year":"2011","unstructured":"Tendera M, Aboyans V, Bartelink M-L, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatm. Eur Heart J [Internet]. 2011;32:2851\u2013906.","journal-title":"Eur Heart J [Internet]"},{"key":"706_CR38","first-page":"CD002071","volume":"8","author":"L Robertson","year":"2012","unstructured":"Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev [Internet]. 2012;8:CD002071.","journal-title":"Cochrane Database Syst Rev [Internet]"},{"key":"706_CR39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ahj.2013.12.012","volume":"167","author":"WS Jones","year":"2014","unstructured":"Jones WS, Dolor RJ, Hasselblad V, et al. Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia. Am Hear J. 2014;167:489\u201398. e7.","journal-title":"Am Hear J"},{"issue":"Suppl 1","key":"706_CR40","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1002\/ccd.21996","volume":"74","author":"RV Milani","year":"2009","unstructured":"Milani RV. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? Catheter Cardiovasc Interv. 2009;74 Suppl 1:S7\u2013S11.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"706_CR41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.avsg.2012.05.001","volume":"27","author":"MT Allemang","year":"2013","unstructured":"Allemang MT, Rajani RR, Nelson PR, et al. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg. 2013;27(1):62\u20137.","journal-title":"Ann Vasc Surg"},{"key":"706_CR42","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jvs.2006.07.044","volume":"44","author":"R Koppensteiner","year":"2006","unstructured":"Koppensteiner R, Spring S, Amann-Vesti BR, et al. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. J Vasc Surg [Internet]. 2006;44:1247\u201353.","journal-title":"J Vasc Surg [Internet]"},{"key":"706_CR43","first-page":"A14976 \u2013","volume":"130","author":"S Cho","year":"2014","unstructured":"Cho S, Ko Y-G, Shin D-H, et al. Abstract 14976: impact of the duration of dual antiplatelet therapy in patients with peripheral arterial occlusive disease after percutaneous transluminal angioplasty on clinical outcomes. Circulation [Internet]. 2014;130:A14976 \u2013.","journal-title":"Circulation [Internet]"},{"key":"706_CR44","unstructured":"Banerjee S, University of Texas Southwestern Medical Center. Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities (ASPIRE PAD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Sep 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02317822 NLM Identifier: NCT02317822."},{"key":"706_CR45","unstructured":"Kashyap VS, University Hospital Case Medical Center. Evaluation of short versus long duration dual antiplatelet therapy in patients undergoing lower extremity endovascular revascularization. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Sep 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02433587 NLM Identifier: NCT02433587."},{"key":"706_CR46","unstructured":"Arkansas Heart Hospital. Ticagrelor and peripheral arterial disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Sep 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02407314 NLM Identifier: NCT02407314."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-016-0706-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-016-0706-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-016-0706-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T07:07:03Z","timestamp":1567580823000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-016-0706-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s11886-016-0706-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]},"article-number":"26"}}